乳腺癌新辅助化疗疗效:磁共振成像汇编(MAGIC)的见解
本研究回顾性分析2021年11月至2024年6月101例乳腺癌患者(114个病灶),按Miller-Payne分级分为pCR组与非pCR组,比较新辅助化疗前后MR参数变化;结果显示ME病灶中post-T1、post-T2及ADC值可有效区分pCR与非pCR,MAGIC技术联合DWI可提高ME病灶pCR诊断准确性,而NME病灶中未见显著差异。
要点
- ME病灶新辅助化疗后T1、T2、PD值下降,ADC值升高,post-T1、post-T2及ADC值可区分pCR与非pCR。
- NME病灶新辅助化疗后MR参数变化无显著差异,MAGIC联合DWI诊断效用有限。
- MAGIC技术联合DWI可提高ME病灶pCR诊断准确性(所有P值<0.05)。
核心结论
- 对于ME乳腺癌,MAGIC技术可有效预测pCR,联合DWI可提高诊断准确性,是临床决策的重要工具;对NME乳腺癌效用有限。
研究设计与样本
- 回顾性分析2021年11月至2024年6月101例乳腺癌患者(114个病灶),按Miller-Payne分级分为非pCR组与pCR组,记录首次NAC前及末次术前MR参数(post-parameters),比较NAC前后MR参数变化。
关键影像表现/征象
- ME与NME病灶NAC后T1、T2、PD值均下降,ADC值均显著升高。
- ME病灶中仅post-T1、post-T2及ADC值(PD除外)可有效区分pCR与非pCR。
- NME病灶中pCR与非pCR间未见显著差异。
诊断标准与关键数值
- pCR定义为Miller-Payne分级达到病理完全缓解。
- 101例患者中36.63%(37/101)达到pCR。
- 114个病灶中68.42%(78/114)为ME病灶。
- MAGIC技术联合DWI提高ME病灶pCR诊断准确性,所有P值<0.05。
临床应用与阅片要点
- 阅片时对ME病灶应关注NAC前后T1、T2及ADC值变化,辅助判断pCR。
- 对NME病灶,NAC前后MR参数变化对pCR判断价值有限。
- 报告ME病灶疗效评估时可结合MAGIC技术与DWI以提高诊断准确性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: This study aimed to investigate the role of Magnetic Resonance Imaging Compilation (MAGIC) technology in diagnosing pathologically complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer with mass enhancement (ME) and non-mass enhancement (NME) lesions.
MATERIALS AND METHODS: A total of 101 breast cancer patients from November 2021 to June 2024 were retrospectively analyzed and divided into the non-pCR group and the pCR group according to the Miller-Payne grade. Magnetic Resonance (MR) parameters before the first NAC and the last preoperative MR examination (post-parameters) were recorded, respectively. To compare the changes in MR parameters before and after NAC in the two types of breast cancer.
RESULTS: One hundred and one breast cancer patients with 114 lesions. 36.63% (37/101) of patients achieved pCR, and 68.42% (78/114) were ME lesions. The T1, T2, and PD values decreased, and the ADC value increased significantly after NAC in both ME and NME lesions. However, only post-T1, post-T2, and ADC values (excluding PD) effectively differentiated pCR from non-pCR in ME lesions, whereas no significant differences were observed in NME lesions. Notably, MAGIC technology combined with DWI significantly enhanced diagnostic accuracy for pCR in ME lesions (all P values < 0.05), but this approach showed limited utility in NME breast cancer.
CONCLUSION: For ME breast cancer, MAGIC technology serves as an important tool for clinical decision-making by effectively predicting pCR and, in combination with DWI, improving the accuracy of diagnosis.
引用
- Wu H, Huang Z, Wang J, et al. Neoadjuvant Chemotherapy Efficacy in Breast Cancer: Insights from Magnetic Resonance Imaging Compilation (MAGIC). Acad Radiol. 2025. PMID: 40318975. doi:10.1016/j.acra.2025.04.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。